Twenty-year study suggests low aerobic levels in young adults may lead to diabetes later in life
NEW YORK Young adults ages 18 to 30 with low aerobic fitness levels are two to three times more likely to develop diabetes in 20 years in comparison with those who are fit, according to a recent study.
The study from researchers at Northwestern University Feinberg School of Medicine also found that on average, young women and young African Americans are less aerobically fit than men and white adults in the same age group, thereby placing them at a higher risk for diabetes.
The study was based predominantly on individuals’ body mass index, a measure of the body’s fat content, in order to determine the participants’ likelihood of developing diabetes.
“The overwhelming importance of a high BMI to the development of diabetes was somewhat unexpected and leads us to think that activity levels need to be adequate not only to raise aerobic fitness, but also to maintain a healthy body weight,” Mercedes Carnethon, lead author and assistant professor of preventive medicine at Northwestern’s Feinberg School, said. “If two people have a similar level of fitness, the person with the higher BMI is more likely to develop diabetes.”
Carnethon continued to explain that unfit young adults can avoid a future with diabetes by exercising and losing weight. This study will be published in the July issue of Diabetes Care.
GSK to develop inflammatory disease treatments with Chroma Therapeutics
LONDON British drug maker GlaxoSmithKline will collaborate with fellow British pharmaceutical company Chroma Therapeutics to develop treatments for such inflammatory diseases as rheumatoid arthritis.
GSK announced Tuesday that it would work with Chroma to use Chroma’s proprietary esterase-sensitive motif technology, which uses amino acid esters to make drugs target cells that cause inflammatory diseases.
Under the terms of the collaboration with GSK’s Center of Excellence for External Drug Discovery, Chroma will seek to discover new pharmaceutical drugs in four discovery and development programs, receiving a “significant” up-front cash payment and an equity financing investment by GSK, as well as potential milestones, royalties and option fees, including possibly more than $1 billion in milestones.
“This agreement marks GSK’s continued efforts to access the best science and technology platforms worldwide,” GSK VP and head of the European CEEDD Shelagh Wilson stated.
Takeda completes acquisition of IDM Pharma
OSAKA, Japan Japanese drug maker Takeda Pharmaceutical Co. completed its tender offer for a company that develops cancer drugs.
Takeda announced Tuesday that it had completed its tender offer to acquire all outstanding shares of IDM Pharma for $2.64 per share, with about 86% of IDM shares tendered.
The two companies originally agreed to the acquisition in May, with Takeda showing particular interest in IDM’s malignant bone cancer drug Mepact (mifamurtide), which European regulators approved in March for marketing in the European Union, Iceland, Liechtenstein and Norway.